CJC-1295 with DAC: Evidence, Mechanism & Legal Status

CJC-1295 with DAC is a long-acting analog of growth-hormone-releasing hormone (GHRH), marketed and used as a growth-hormone secretagogue for purported fat loss, recovery and anti-aging. It is best known for the engineering trick in its name: the Drug Affinity Complex, or DAC, which covalently bonds the peptide to circulating albumin and turns a drug that normally clears in minutes into one that works for days.3 Its popularity in performance and longevity circles is large; its proof for any clinical benefit is not. This monograph separates the biomarker effect that is genuinely proven from the outcomes that are merely assumed.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. CJC-1295 with DAC is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is CJC-1295 with DAC and how does it work?

CJC-1295 is built on the GHRH(1-29) backbone — the same fragment as sermorelin — with four stabilizing substitutions (D-Ala2, Gln8, Ala15, Leu27) that protect it from dipeptidyl-peptidase-IV and endopeptidase cleavage. The defining DAC feature is a fifth modification: an Nε30-maleimidopropionyl-lysine appended at the C-terminus. The molecule was developed by ConjuChem Biotechnologies as "DAC:GRF," with molecular formula C165H269N47O46 and a molar mass near 3,647 g/mol.3

The core mechanism — and the entire reason the drug lasts for days — is the albumin tether. After subcutaneous injection, the reactive maleimide of the DAC undergoes a Michael-addition bioconjugation with the free thiol of cysteine-34 on serum albumin, forming a stable covalent peptide-albumin adduct in the bloodstream. Albumin's long circulatory residence and large hydrodynamic size shield the peptide from enzymatic degradation and renal filtration, effectively turning albumin into a slow-release depot. This is what stretches the terminal half-life into the multi-day range, versus about 30 minutes for the no-DAC modified GRF(1-29) and roughly 5-7 minutes for native GHRH.311 Once in circulation, the peptide binds the pituitary GHRH receptor on somatotrophs, activating Gs/adenylyl-cyclase to cAMP signaling that releases growth hormone, which in turn drives hepatic and peripheral IGF-1. Because the DAC creates continuous receptor occupancy, it blunts the body's normal pulsatile GH rhythm, producing a sustained "GH bleed" rather than discrete nocturnal pulses — a point the source material flags as a departure from physiology, not a restoration of it.12

What is the evidence by indication?

The evidence picture is sharply tiered: one endpoint has real randomized human data, and everything else is extrapolation. The pivotal program was a pair of small Phase 1 ascending-dose RCTs by Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism in 2006 — you can read the abstract on PubMed (PMID 16352683).1 The table below grades each indication.

The one solid endpoint is the biomarker effect. The Teichman program comprised two randomized, double-blind, placebo-controlled, ascending-dose Phase 1 trials (28- and 49-day designs across two sites, healthy adults aged 21-61, single and weekly or biweekly subcutaneous dosing). The results were unambiguous and dose-dependent: GH rose 2- to 10-fold for at least 6 days and IGF-1 rose 1.5- to 3-fold for 9-11 days per single injection, with cumulative IGF-1 elevation above baseline for up to 28 days on repeated dosing.12 Sample sizes were small — reported across sources as roughly 21 to 34 subjects total across cohorts — so this is robust proof of mechanism but not outcome-level efficacy.

Every other claim is weaker. Body-composition benefit is frequently marketed but has never been demonstrated in a completed Phase 2/3 RCT; the claim rests on the assumption that sustained GH/IGF-1 elevation translates to fat loss or lean-mass gain, an inference borrowed from recombinant-GH literature rather than a CJC-1295 trial result.3 CJC-1295 was investigated historically for HIV-associated lipodystrophy, but it reached only Phase 2 before discontinuation; the related, FDA-approved GHRH analog tesamorelin, which lacks DAC, carries the actual approved lipodystrophy indication.3 Recovery, injury healing, sleep and anti-aging have no controlled human support whatsoever and should be treated as unproven.12

What doses appear in the literature?

Reported strictly as information, not a protocol. All human dosing was subcutaneous.1 In the Phase 1 program, ascending single doses and two-to-three weekly or biweekly doses were used, and the investigators reported 30 µg/kg and 60 µg/kg as the best-tolerated dose levels.1 The multi-day half-life is the entire rationale for the DAC: it permits weekly or even biweekly dosing, in contrast to the no-DAC modified GRF(1-29), which with its roughly 30-minute half-life requires multiple daily injections to maintain an effect.1112 Outside trials, non-clinical anti-aging use is commonly cited around 1-2 mg subcutaneously once or twice weekly — but this is ungraded anecdote, not a validated dose.3 The compound is supplied as a lyophilized powder reconstituted with bacteriostatic water; oral bioavailability is negligible because it is a peptide, so it is designed for parenteral use, and research-use products carry no GMP, sterility or identity guarantees.

How safe is CJC-1295 with DAC?

The most frequent adverse events in the Phase 1 trials were injection-site reactions — transient pain, swelling and induration, sometimes with local urticaria — and no serious adverse reactions were reported in the controlled studies.1 The more significant signal comes from the development program itself, which was terminated at Phase 2 after the death of a trial participant. The attending physician attributed the death to asymptomatic coronary artery disease with plaque rupture and occlusion and deemed it unrelated to the drug, but research ended as a precaution — meaning the long-term safety of sustained GH/IGF-1 elevation from this agent was never fully characterized in humans.3

By analogy to recombinant GH and other GH secretagogues, chronic elevation of GH and IGF-1 carries plausible risks of fluid retention and edema, arthralgia and carpal-tunnel-type symptoms, insulin resistance and glucose dysregulation, and — most importantly — a theoretical neoplasia and angiogenesis concern, because IGF-1 is mitogenic and anti-apoptotic. The FDA additionally flagged CJC-1295 for immunogenicity (aggregation in injectable formulations) and peptide-related impurity concerns.5 Theoretically contraindicated or cautioned populations, by GH/GHRH-class precaution rather than CJC-1295-specific data, include anyone with active or prior malignancy, pregnancy and lactation, uncontrolled diabetes, and critically ill states. It may oppose glucose control, so caution is warranted alongside insulin or oral hypoglycemics.9

What is the FDA and WADA status in 2026?

CJC-1295 with DAC is not an FDA-approved drug for any indication; it is an abandoned investigational compound.3 The compounding timeline is precise. In September 2023 the FDA placed several peptides, including CJC-1295, in Category 2 of the interim 503A bulk-substances policy, meaning they could not be used in compounding while under review.6 On September 20/27, 2024 the FDA removed five substances — AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1 and Selank — from Category 2 after the nominators withdrew their nominations, a procedural removal, not a safety clearance.6 Then on December 4, 2024 the Pharmacy Compounding Advisory Committee voted against including CJC-1295-related substances — explicitly the free base, acetate, CJC-1295 with DAC free base, DAC acetate and DAC trifluoroacetate — on the 503A bulks list, citing immunogenicity, characterization and the absence of an approved indication.47 The net status for 2026: not on the approved 503A bulks list and recommended against by PCAC, therefore not eligible for routine compounding pending any further FDA action.6

For athletes the picture is unambiguous. CJC-1295 is prohibited at all times, in and out of competition, under WADA section S2.2.4, Growth Hormone Releasing Factors, where the GHRH analogs CJC-1293 and CJC-1295 are named explicitly; the 2026 Prohibited List took effect on January 1, 2026.89 Because of the long half-life it is detectable for 28 or more days after a single dose, and strict liability applies regardless of dose, route or research-grade labeling.10 Any WADA-tested athlete or military service member should treat it as banned.

Bottom line. CJC-1295 with DAC does exactly what a long-acting GHRH agonist should do to blood markers — small, well-designed Phase 1 RCTs prove it raises GH 2-10x and IGF-1 1.5-3x for days, cumulatively up to 28 days, a Grade B and real biomarker effect.1 Everything beyond it — fat loss, lean mass, recovery, anti-aging — is unproven C/D, because development stopped at Phase 2 (after a participant death deemed unrelated but treated as a stop signal) and no clinical-outcome RCT exists. The most important uncertainties are the safety of chronic, non-pulsatile GH/IGF-1 elevation and the absence of any quality-controlled, approved product. The regulatory verdict matches the evidence: not FDA-approved, rejected by PCAC for compounding in December 2024, and banned in all sport by WADA. Regulatory facts here are current as of June 2026 and should be re-verified for later developments.